Summary
All provided claims are marked as absent from the (not provided) FDA-approved labeling, so label alignment cannot be established.
Category Scores
Accurate Statements
Unsupported Statements
“Loss of exclusivity” means the period during which the company that markets guselkumab (Tremfya) has legal market protection ends.
Marked absent from the label.
When legal market protection ends, competitors may be able to market biosimilars or (in some cases) other competing products.
Marked absent from the label.
The exact timing of loss of exclusivity depends on patents (and their expiry dates) and on any regulatory exclusivities in the relevant country, not only on the drug’s approval date.
Marked absent from the label.
Once exclusivity and/or key patents expire (or are successfully cleared in litigation), biosimilar manufacturers can typically seek to launch at lower prices.
Marked absent from the label.
Biosimilar launches after exclusivity and/or key patents expire can lead to competitive price pressure and wider formulary access.
Marked absent from the label.
The pace of price pressure and wider formulary access depends on which patents expire first (or are found invalid/unenforceable).
Marked absent from the label.
The pace depends on whether biosimilars have been approved by regulators by the time exclusivity ends.
Marked absent from the label.
The pace depends on payor contracting and local formulary rules.
Marked absent from the label.
For guselkumab, “loss of exclusivity” discussions are most often about patents rather than a single regulatory exclusivity “clock.”
Marked absent from the label.
For guselkumab, patents can extend market protection even after initial approval.
Marked absent from the label.
Patent challenges and court rulings can delay biosimilar launches even after a company expects exclusivity to end.
Marked absent from the label.
Patent challenges and court rulings can accelerate biosimilar launches if a blocking patent is invalidated.
Marked absent from the label.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Claims are about market exclusivity/patent timing and do not directly describe patient dosing, safety, contraindications, or administration. However, they are not supported by FDA labeling based on the provided evaluation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
All provided claims are absent from the FDA-approved labeling (no label sections were available), so label alignment cannot be demonstrated.
Suggested Improvement
Limit statements to information explicitly present in the FDA-approved prescribing information; provide and cite specific label sections (e.g., Clinical Pharmacology, Indications, Warnings) if making any drug-label-related claims.